Supplementary Material for: Roxadustat on renal anemia with macroinflammation: a retrospective cohort study

Introduction: Roxadustat, the first-in class drug for treatment of renal anemia, has demonstrated efficacy in renal anemia with microinflammation. Additional data are needed regarding the efficacy of roxadustat on renal anemia with systemic macroinflammation. Methods: Three cohorts of renal anemia based on the basic level of high-sensitivity CRP were included. Patients with hsCRP≤2 mg/L were selected as non-inflammation (NI) group; 20.05, respectively). Meanwhile, compared with that of NI group, there was no significant difference in hemoglobin response rate in the MA group both at weeks 12 (p=0.06; 95% CI, 0.9531 to 13.75) and weeks 52 (p=0.37; 95% CI, 0.5080 to 7.937). Moreover, the hemoglobin response was independent of baseline hsCRP level (p=0.72, 95% CI, -0.1139 to 0.0794). More importantly, roxadustat significantly reduced ferritin, serum iron level, and increased total iron binding capacity in the three groups, which showed no significant differences among the three groups (p>0.05, respectively). Conclusion: Roxadustat significantly improves anemia in CKD patients with systemic macroinflammation.